PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2009-03-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00864786
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 607
- Registration Number
- NCT00864097
- Locations
- 🇦🇹
LKH-Medizinische Universitatsklinik Graz, Graz, Austria
🇦🇹Nuhr Zentrum, Senftenberg, Austria
🇦🇹ClinPharm International GmbH, Wien, Austria
Tanezumab and Nerve Function In Arthritis Patients
- Conditions
- Osteoarthritis
- Interventions
- Biological: tanezumabOther: Placebo
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT00863772
- Locations
- 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸JDP Medical Research, LLC, Aurora, Colorado, United States
🇺🇸Alpine Neurology, Centennial, Colorado, United States
Tanezumab in Osteoarthritis of the Hip or Knee (2)
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 849
- Registration Number
- NCT00863304
- Locations
- 🇺🇸
Greystone Medical Research, LLC, Birmingham, Alabama, United States
🇺🇸Saadat Ansari, MD, Huntsville, Alabama, United States
🇺🇸Coastal Clinical Research, Inc., Mobile, Alabama, United States
Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2009-04-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT00862888
- Locations
- 🇬🇧
Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom
A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers.
- Conditions
- Healthy
- Interventions
- Drug: Treatment ADrug: Treatment CDrug: Treatment B
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2009-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00862667
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State
- Conditions
- Hepatitis C Virus
- Interventions
- Drug: Pharmacokinetics
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00861458
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CP- 690,550 and TacrolimusDrug: CP- 690,550 and Cyclosporine
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00860496
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects
- Conditions
- Falciparum Malaria
- Interventions
- Drug: Flavoquine®, Camoquin® Suspension
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2010-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00859807
- Locations
- 🇮🇳
Pfizer Investigational Site, Navi Mumbai, Maharashtra, India
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2013-09-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 91
- Registration Number
- NCT00858780
- Locations
- 🇸🇪
Pfizer Investigational Site, Uppsala, Sweden